Acid ceramidase and its inhibitors: a de novo drug target and a new class of drugs for killing glioblastoma cancer stem cells with high efficiency

Glioblastoma remains the most common, malignant primary cancer of the central nervous system with a low life expectancy and an overall survival of less than 1.5 years. The treatment options are limited and there is no cure. Moreover, almost all patients develop recurrent tumors, which typically are...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Oncotarget
Egile Nagusiak: Doan, Ninh B., Alhajala, Hisham, Al-Gizawiy, Mona M., Mueller, Wade M., Rand, Scott D., Connelly, Jennifer M., Cochran, Elizabeth J., Chitambar, Christopher R., Clark, Paul, Kuo, John, Schmainda, Kathleen M., Mirza, Shama P.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Impact Journals LLC 2017
Gaiak:
Research Paper
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5762539/
https://ncbi.nlm.nih.gov/pubmed/29348854
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.22637
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak